uploads/2018/05/hand-1106934_1280.jpg

How Much Upside Potential Does Celgene Offer?

By

Updated

Company overview

Celgene (CELG) is a global biopharmaceutical company with a focus on discovering, developing, and marketing innovative therapies for treating cancer and inflammatory diseases. Celgene implements solutions in homeostasis, immune-oncology, epigenetics, and neuroinflammation.

Article continues below advertisement

Analysts’ recommendations

Celgene reported its 1Q18 earnings on May 4. Of the 30 analysts covering Celgene in May, 15 analysts gave the stock a “buy” or higher rating. Fourteen analysts gave Celgene a “hold” rating, and one analyst gave the stock a “sell” rating. The mean rating for Celgene stock is 2.3 with a target price of $113.68, implying an upside potential of 36.6% over its price of $83.24 on May 8.

Peers’ ratings

Of the 23 analysts covering Johnson & Johnson (JNJ) in May, 12 analysts gave the stock a “buy” or higher rating. Eight analysts gave it a “hold” rating, and three analysts gave Johnson & Johnson a “sell” or lower rating. The mean rating for the stock is ~2.4 with a target price of $145.00.

Of the 22 analysts covering Pfizer (PFE) in May, 11 analysts gave the stock a “buy” or higher rating, nine analysts gave it a “hold” rating, and two analysts gave Pfizer a “strong sell” rating. The mean rating for the stock is ~2.6 with a target price of $39.89.

Of the 21 analysts covering Merck (MRK) in May, 16 analysts gave the stock a “buy” or higher rating, and five analysts gave it a “hold” rating. The mean rating for the stock is ~2.0 with a target price of $68.00.

In the next part of this series, we’ll take a look at the performance of Celgene’s key products.

Advertisement

More From Market Realist